Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $166

Benzinga Newsdesk www.benzinga.com Negative 88.1%

Neg 88.1% Neu 0% Pos 0%

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $168 to $166.